Intended for healthcare professionals


Guidelines on neuraminidase inhibitors in children are not supported by evidence

BMJ 2004; 328 doi: (Published 22 January 2004) Cite this as: BMJ 2004;328:227
  1. Mkael Symmonds, preregistration house officer (,
  2. Nicholas J Matheson, preregistration house officer,
  3. Anthony Harnden, university lecturer
  1. Department of Surgery, Ayr Hospital, Ayr KA6 6DX
  2. Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DU
  3. Department of Primary Health Care, Institute of Health Sciences, Oxford OX3 7LF

    EDITOR—Guidelines from the National Institute for Clinical Excellence (NICE) on the use of neuraminidase inhibitors recommend oseltamivir for the treatment of at risk children with influenza-like illness of fewer than 48 hours' duration—for example, those with underlying chronic respiratory disease.1 The drug is not recommended for otherwise healthy children.

    In our systematic review on the use of neuraminidase …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription